Myeloproliferative Neoplasms News

Four oncology leaders have been elected to ASCO’s board of directors.

Scrambler therapy is a pain management approach that uses a machine to block the transmission of pain signals by providing non-pain information to nerve fibers that have been receiving pain messages.

ORLANDO, Fla. — Aaron Gerds, MD, discusses key research related to myeloproliferative neoplasms presented at the ASH Annual Meeting and Exposition.

Researchers at University of Michigan Comprehensive Cancer Center developed a new first-of-its-kind mobile app to help patients with breast cancer manage and navigate the multitude of information that accompanies a cancer diagnosis.

More than half of hematologic oncologists surveyed reported they conduct end-of-life conversations with their patients at too late a stage, according to a research letter published in JAMA Internal Medicine.

Issues surrounding nutrition and weight management are significantly more pressing now than they were decades ago when obesity was relatively uncommon.

ORLANDO, Fla. — The addition of eltrombopag to immunosuppressive treatment increased complete hematologic response rates in patients with treatment-naive severe aplastic anemia, according to results of a late-breaking abstract presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — Eltrombopag improved platelet counts and alleviated fatigue among low-risk patients with myelodysplastic syndromes who experienced severe thrombocytopenia, according to results of a phase 2 placebo-controlled study presented at the ASH Annual Meeting and Exposition.

ORLANDO, Fla. — The fusion protein luspatercept led to a sustained increase in hemoglobin levels and reduced the transfusion requirement among patients with low- or intermediate-risk myelodysplastic syndromes, according to preliminary data from a phase 2 study presented at the ASH Annual Meeting and Exposition.

Cancer affects not only the patient, but also family and friends who care for that person.